Vericel Corporation (VCEL)
NASDAQ:VCEL
Want to see VCEL full AI Analyst Report?
VCEL Stock Chart & Stats
$35.68
$1.36(2.35%)
At close: 4:00 PM EST
$35.68
$1.36(2.35%)
Day’s Range― - ―
52-Week Range$28.95 - $45.97
Previous CloseN/A
Volume83.17K
Average Volume (3M)634.64K
Market Cap
$1.77B
Enterprise Value$1.76B
Total Cash (Recent Filing)$145.34M
Total Debt (Recent Filing)$94.42M
Price to Earnings (P/E)―
Beta1.00
Next Earnings
Aug 05, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)0.43
Shares Outstanding51,068,230
10 Day Avg. Volume612,652
30 Day Avg. Volume634,640
Financial Highlights & Ratios
PEG Ratio1.93
Price to Book (P/B)5.14
Price to Sales (P/S)6.59
P/FCF Ratio73.61
Enterprise Value/Market Cap0.99
Enterprise Value/Revenue6.02
Enterprise Value/Gross Profit8.05
Enterprise Value/Ebitda52.75
Forecast
1Y Price Target
$61.25Price Target Upside71.66% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering6
EPS Forecast (FY)0.47
Revenue Forecast (FY)$323.43M
Bulls Say, Bears Say
Bulls Say
Commercial Expansion And Surgeon AdoptionCompleted expansion of the MACI sales force and a growing number of trained surgeons is increasing biopsy and implant activity, deepening product penetration and supporting sustained top-line growth.
Government ContractLong-term federal procurement agreement for NexoBrid secures recurring procurement revenue, offsets development costs, and could fund a room-temperature formulation and U.S. manufacturing to strengthen profitability and pipeline advancement.
Profitability And Cash FlowRecord revenue combined with stronger gross margins has driven renewed GAAP net income profitability and improved cash generation, reducing financial risk and enabling reinvestment in growth initiatives.
Bears Say
Commercial Ramp ExecutionSlower-than-expected commercialization at individual burn centers has delayed full revenue realization from the burn care franchise and creates dependency on additional catalysts to restore momentum.
Margin Pressure From InvestmentsHigher costs related to a new manufacturing facility, expanded sales headcount, and clinical programs are pressuring adjusted EBITDA margins and could constrain near-term profitability expansion.
Valuation RiskAnalyst neutral rating reflects that the stock trades at a premium to peers, limiting upside unless growth and profitability accelerate beyond current expectations.
Vericel News
VCEL FAQ
What was Vericel Corporation’s price range in the past 12 months?
Vericel Corporation lowest stock price was $28.95 and its highest was $45.97 in the past 12 months.
What is Vericel Corporation’s market cap?
Vericel Corporation’s market cap is $1.77B.
When is Vericel Corporation’s upcoming earnings report date?
Vericel Corporation’s upcoming earnings report date is Aug 05, 2026 which is in 73 days.
How were Vericel Corporation’s earnings last quarter?
Vericel Corporation released its earnings results on May 07, 2026. The company reported -$0.12 earnings per share for the quarter, beating the consensus estimate of -$0.153 by $0.033.
Is Vericel Corporation overvalued?
According to Wall Street analysts Vericel Corporation’s price is currently Undervalued.
Does Vericel Corporation pay dividends?
Vericel Corporation does not currently pay dividends.
What is Vericel Corporation’s EPS estimate?
Vericel Corporation’s EPS estimate is -0.02.
How many shares outstanding does Vericel Corporation have?
Vericel Corporation has 51,068,230 shares outstanding.
What happened to Vericel Corporation’s price movement after its last earnings report?
Vericel Corporation reported an EPS of -$0.12 in its last earnings report, beating expectations of -$0.153. Following the earnings report the stock price went down -4.486%.
Which hedge fund is a major shareholder of Vericel Corporation?
Currently, no hedge funds are holding shares in VCEL
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Vericel Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$61.25 (71.66% Upside)
$61.25 (71.66% Upside)
Blogger Sentiment
Neutral
VCEL Sentiment 50%
Sector Average ―
Sector Average ―
Hedge Fund Trend
Decreased
By 5.0K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $327.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▲ 1.5%
Last 30 Days ▼ 0.3%
Last 30 Days ▼ 0.3%
News Sentiment
Very Bullish
Bullish news 99%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.07%
12-Months-Change
Fundamentals
Return on Equity
6.41%
Trailing 12-Months
Asset Growth
14.38%
Trailing 12-Months
Company Description
Vericel Corporation
Vericel Corporation, a commercial-stage biopharmaceutical company, engages in the research, development, manufacture, and distribution of cellular therapies for sports medicine and severe burn care markets in the United States. The company markets autologous cell therapy products comprising MACI, an autologous cellularized scaffold product for the repair of symptomatic, and single or multiple full-thickness cartilage defects of the knee; and Epicel, a permanent skin replacement humanitarian use device for the treatment of adult and pediatric patients with deep-dermal or full-thickness burns. Its preapproval stage product is NexoBrid, a registration-stage biological orphan product for eschar removal in adults with deep partial-thickness and/or full-thickness thermal burns. The company was formerly known as Aastrom Biosciences, Inc. Vericel Corporation was incorporated in 1989 and is headquartered in Cambridge, Massachusetts.
VCEL Company Deck
VCEL Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed a strongly positive operational and financial quarter: record revenue, double-digit MACI growth, materially improved margins, robust cash generation, successful sales force expansion, regulatory and manufacturing milestones, and a meaningful BARDA award. The key near-term risks are timing and contingent nature of BARDA-related revenue, the need to sustain biopsy-to-implant conversion, modest near-term margin variability due to investments, and external macro/access uncertainties. On balance, the positives substantially outweigh the challenges.View all VCEL earnings summariesVCEL Stock 12 Month Forecast
Average Price Target
$61.25
▲(71.66% Upside)
Technical Analysis
Ownership Overview
1.20% Insiders
32.87% Mutual Funds
37.73% Other Institutional Investors
4.40% Public Companies and
Individual Investors